MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
TLGT - Teligent Inc
$0.98
-0.03(-2.67%)8:59:56 PM 2/25/2021
Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's topical semi-solid and liquid products are used in various applications that range from cosmetics and cosmeceuticals; and the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. It sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    02/23/2021TLGT
    Teligent, Inc. Announces Appointment of Carter Pate to Board of Directors

    Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed Carter Pate to its Board of Directors, effective immediately. Mr. Pate will serve on the Audit and Nominating and Corporate Governance Committees.

    02/16/2021TLGT
    Teligent, Inc. Announces Appointment of William S. Marth to Board of Directors

    Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed industry veteran William S. Marth to its Board of Directors, effective immediately. Mr. Marth brings over 25 years of expertise and a proven track record of leading companies in the generic pharmaceutical and contract manufacturing industries.

    01/28/2021TLGT
    The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 27) Abbott Laboratories (NYSE: ABT) (reacted to fourth-quarter results) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) Atea Pharmaceuticals Inc (NASDAQ: AVIR) AtriCure Inc. (NASDAQ: ATRC) Aziyo Biologics Inc (NASDAQ: AZYO) Cassava Sciences Inc (NASDAQ: SAVA) Collegium Pharmaceutical Inc (NASDAQ: COLL) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN) Corcept T...

    01/28/2021TLGT
    Teligent Takes Strategic Steps to Recapitalize and Position Business for Success

    Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced a series of strategic actions in partnership with its senior lenders and its Series C noteholders to recapitalize and enhance the Company's financial flexibility. Through these actions and with support from its senior lenders and Series C noteholders, the Company is strengthening its balance sheet while also working to raise additional capital and position it...

    01/22/2021TLGT
    Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule

    BUENA, N.J., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, previously received notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company not having timely filed its Quarterly Report on Form 10-Q for the three months ended September 30, 2020 (the “Form 10-Q”) with the Securities and Exchange...

    12/31/2020TLGT
    Teligent, Inc. Announces Third Quarter 2020 Results

    BUENA, N.J., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020.Financial HighlightsThird Quarter 2020 vs. Second Quarter 2020 * Revenues of $14.3 million, an increase of $0.8 million or 6%, on stronger demand for US topical products * Gross profit of $0.1 million, a decrease of $2.4 million driven by additional inventory reserves a...

    11/25/2020TLGT
    Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders

    Scheduled to Reconvene on December 16, 2020 Company Urgently Encourages Stockholders to VoteBUENA, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of Stockholders, scheduled for October 22, 2020, adjourned to November 11, 2020 and then to November 25, 2020, was convened and adjourned without any business being conducted due to the fact that a quorum was no...

    10/22/2020TLGT
    Looking Into Teligent's Return On Capital Employed

    During Q2, Teligent (NASDAQ: TLGT) brought in sales totaling $13.59 million. However, earnings decreased 75.81%, resulting in a loss of $4.37 million. In Q1, Teligent brought in $7.45 million in sales but lost $18.05 million in earnings.Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth ...